Diltiazem ER

DRUG4 trials

Sponsors

Mutual Pharmaceutical Company, Inc., Viatris Innovation GmbH, Bristol-Myers Squibb, Eisai Co., Ltd.

Conditions

Healthy SubjectsHealthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoproteinThrombosis

Phase 1

Drug-Drug Interaction Study Between Colchicine and Diltiazem ER

CompletedNCT00983372

Mutual Pharmaceutical Company, Inc.Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein

Start: 2008-08-31End: 2008-08-31Updated: 2009-10-15

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

TerminatedNCT02479204

Viatris Innovation GmbHHealthy Subjects

Start: 2015-04-28End: 2016-05-01Updated: 2025-09-22

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects

CompletedNCT02807909

Bristol-Myers SquibbThrombosis

Start: 2016-07-31End: 2016-08-31Updated: 2016-09-12

Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects

CompletedNCT02947711

Eisai Co., Ltd.Healthy Subjects

Start: 2016-10-31End: 2017-01-31Updated: 2017-03-07

Related Papers

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.

2022-05-3115 citations